Navigation Links
Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/4/2008

VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne Kay, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at 10:20 a.m. Eastern time at The New York Palace Hotel in New York City.

A Web cast of the presentation will be available at http://wsw.com/webcast/rrshq14/rbm.cn, during the event and will be archived and available on a link through the corporate Web site (http://www.responsebio.com) for 90 days.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests worldwide and in 2008 entered into a strategic alliance with Roche Diagnostics to commercialize rapid cardiovascular tests worldwide.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at http://www.responsebio.com.


'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical Closes $5.1 Million Financing
2. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
3. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference
4. Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing
5. Response Biomedical Announces Insider Participation in Current Financing
6. Hurricane Ike: World Vision Readies Supplies, Staff, Volunteers for Response
7. Monitoring immune responses in disease
8. Gustav: World Vision Teams Assist Evacuees in Jackson and Dallas, Prepare Response
9. Immune Response May Hinder Stem Cell Treatments
10. Study sees need for standardized evaluation of antibody response to HIV-1
11. Presidents Award Recognizes Hospitals Response to Bridge Collapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... and Android devices. VisualDx is the first point of care diagnostic support ... general medicine. The system speeds diagnosis, therapy decisions and patient education for ...
(Date:5/5/2016)... ... ... is just around the corner. Summer means a lot of different things to people. ... all day and night. Parents often lament the coming of summer as they will have ... trips to the beach, backyard cookouts, fireworks on the Fourth of July, and even perhaps ...
(Date:5/5/2016)... ... , ... Dermatologic surgeons performed nearly 10 million medically necessary and cosmetic procedures ... , The results of the 2015 ASDS Survey on Dermatologic Procedures released today reveal ... the growing popularity of soft-tissue fillers and body sculpting procedures. , For the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... , The Medical Society of Northern Virginia, Announces DoctorsTelemed?, A telehealth ... Medical Society of Northern Virginia (MSNVA) launches DoctorsTelemed?, a telemedicine solution that ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Nepenthe Laboratory Services ... Elementary School last week to raise non-perishable food item donations for Food for Lane ... Day” hosted on NBC. , “The goal of the assembly was to create an ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016  It,s time for an upgrade. There are many medical recorders ... 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix ... a world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology: